Code : 9345-351040      Created Date : Saturday, March 5, 2016   Visit : 1911

The 9th World Congress of the World Society for Pediatric Infectious Diseases

The report of The 9th World Congress of the World Society for Pediatric Infectious Diseases by Dr. Vahid Salimi
Application Code :
306-0116-0018
 
Created Date : Sunday, January 17, 2016 12:36:31Update Date : Sunday, January 17, 2016 14:12:07
IP Address : 194.225.57.40Submit Date : Sunday, January 17, 2016 14:12:49Email : vahidsalimii@gmail.com
Personal Information
Name : Vahid
Surname : Salimi
School/Research center : School of Public Health
If you choose other, please name your Research center :  
Position : Assistant professor
Tel : +98-21-88962343
Information of Congress
Title of the Congress : The 9th World Congress of the World Society for Pediatric Infectious Diseases
Title of your Abstract : Is the routine measles vaccine protective against recent measles virus genotypes?
Destination Country : Brazil
From : Wednesday, November 18, 2015
To : Sunday, November 22, 2015
Abstract(Please copy/paste the abstract send to the congress) :
Background: Despite the accessibility of a promising measles virus (MV) vaccine, measles outbreaks take place even in well vaccinated populations. From all 24 known genotypes of MV, D4, H1 and B3 genotypes have been detected from different regions in Iran. It is necessary to evaluate the protective efficacy of vaccine against currently circulating MV genotypes in elimination phase. 
Methods: Forty serum samples were selected from individuals with an age range of 4-5 years old after at least two months of vaccination by MMR. A focus reduction neutralization test (FRNT) was developed to measure the neutralizing antibody titers against different genotypes of MV, such as H1, D4, B3 and A (vaccine strain).
Results: The geometric mean titer (GMT) of the sera against D4, H1, B3 and A genotypes were 1:98, 1: 93, 1:32, 1:79, respectively. Low GMT of antibody against B3 genotype was detected comparing to other genotypes. Also a significant difference in plaque size between genotype B3 with both H1 and D4genotypes was observed. 
Conclusion: Our results indicated that the anti-MV antibody titers in the sera of vaccinees are sufficient to neutralize all circulating genotypes. However neutralizing antibody titers against B3 genotype was significantly lower than the H1, D4 and A genotypes. Since the size of B3 plaque had significant differences compared to both genotypes H1 and D4 but not genotype A, so the diameter of plaque may be indicative of the pathogenicity of the virus which requires further evaluations to clarify the relation of virus pathogenicity and their plaque size. 
Keywords of your Abstract : measles vaccine, easles virus genotypes, FRNT, plaque size, Iran
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/13504/Forms/306/Acceptance letter_3.pdf
The presentation : Poster
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/13504/Forms/306/BOOK_1.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/13504/Forms/306/abstract_in_the_abstract_book.pdf
Where has your abstract been indexed? : other
If you choose other, please name : http://wspid.kenes.com/congress-information/general-information
The Congress Reporting Form
How many volunteers were present at the Congress? : 2500-3000
Delegates from which countries presented in the congress? : Most of the countries all over the world including Brazil, USA, UK, Germany, Netherlands, New Zealand, Japan, Italy, Spain, South Africa, Sweden, Canada, China, Iran, Turkey, India, ...
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : WSPID, ESPID
What were the responses to your talking points? Were specific questions or concerns raised? : For years there has been a debate on whether or not the new genotypes of measles ( such as B3, D4, H1, D9, D8, ... ) are not sufficiently neutralized by the measles vaccines, which are based on a genotype (A) that was circulating in the 50s. Therefore presentation of our own experiences raised many questions for scientists from other countries that what is the protective efficacy of vaccine against currently circulating measles virus genotypes? There were also some requests from me to explain the details of our method about focus reduction neutralization test (FRNT). I also had a valuable discussion with measles specialist from Australia and UK.
If you met staff members, please list their full names & positions. : Dr. Eitan Berezin from Brazil
Dr. Mark Cotton from South Africa
Dr. Keith Klugman from USA
 
Please inform us if there are any follow up actions we need to talk with the members of the congress : It is a good idea to make a contact with WSPID representative for organizing a mutual programs in our country. There were several "Meet the Professor" Sessions offered during the congress. The “Meet the Professor Sessions” provided participants the opportunity to be updated about the topic of interest in a highly interactive manner. It will be valuable if we can manage this kind of activities in our national congress.
Your experiences about the travel processes(Providing ticket, accommodation,...) : I had no specific problem, however booking the hotel and online money transferring is still difficult from our country.
Please give a briefing of your own observations and outcomes of the congress: : The WSPID is a confederation of Pediatric Infectious Diseases (PID) societies. The WSPID aspires to create a global network of national and international PID societies for exchange of information and knowledge between the societies. The Programme Committee of WSPID 2015 had been created a comprehensive series of keynote lectures, symposia, educational workshops and meet-the-professor sessions, covering the entire field of paediatric infection-related diseases and involving a large number of internationally renowned experts. The programme includes regular interactive presentations highlighting the results of applied research and the lessons learned in clinical and laboratory practice. The company’s exhibition area was also very interesting for getting familiar with new vaccines, drugs and technologies. One of the interesting news during the congress was about production of RSV vaccine in the near future.

 

Your Comments :
captcha
Close